INS and prostate carcinoma: Proteolysis of IGFBPs regulates the bioavailability of IGFs, and because of the association between IGF levels and prostate cancer [33], strategies for the direct inhibition of IGF signaling, by inhibiting proteolytic activity, is a potential therapeutic strategy and would likely not interfere with insulin signaling [34].